Donate to save lives this Breast Cancer Awareness Month.
This study is investigating the safety, tolerability and pharmacokinetic (PK) profile of LYT-100 in healthy volunteers and in those with breast cancer-related lymphoedema.
Who is it for?
Patients with breast cancer-related lymphoedema
Part 1 is a multiple ascending dose trial in healthy volunteers (HV) of LYT-100 to determine safety, tolerability, and pharmacokinetic (PK) profile under fed conditions.
Part 2 is a single dose safety, tolerability, and PK trial in HV of LYT-100 under fasted conditions.
Part 3 is a trial of up to six-months duration for safety, tolerability, PK, biomarkers and exploratory clinical assessments in breast cancer patients with secondary lymphoedema.
Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at firstname.lastname@example.org
Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to email@example.com